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Abstract
Background: Although histone methyltransferases EZH2 has been proved to have significant regulatory effect on
the immune rejection after hematopoietic stem cell transplantation, its role in solid-organ transplantation remains
uncovered. In this study, we investigate whether histone methylation regulation can impact renal allograft rejection
in rat models.
Results: Allogeneic rat renal transplantation model (Wistar to Lewis) was established, and the recipients were
administrated with EZH2 inhibitor DZNep after transplantation. Renal allografts and peripheral blood were collected on
day 5 after transplantation for histological examination and mechanism investigation. We found that inhibition of EZH2
by DZNep after transplantation significantly ameliorated acute rejection (AR), with decreased histological injury
and reduced inflammatory infiltration in renal allografts. Attenuation of AR was due to the prohibited activation of
alloreactive T cells, the subsequent impaired production of inflammatory cytokines, and also the elevated apoptosis of
alloreactive T cells in both renal allografts and periphery. However, inhibition of EZH2 did not increase the regulatory T
cells during the AR.
Conclusions: Disruption of EZH2 by DZNep suppressed the immune responses of alloreactive T cells and ameliorated
AR of renal allografts. This suggests a therapeutic potential of targeting histone methyltransferases EZH2 in treating
allograft rejection after solid organ transplantation.
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Background
In solid organ transplantation, the allogeneic T cells are
crucial player during the pathogenesis of immune rejec-
tion, since it’s not only the direct mediator of acute cellu-
lar rejection, but also synergizes the subsequent humoral
rejection [1]. Therefore, comprehensive understanding of
the allogeneic T cell regulation is still necessary for the
better control of transplantation rejection. In recent years,
more and more evidences demonstrated the regulatory ef-
fect of epigenetic modifications in T cell immune response
[2–7]; however, whether these regulation mechanisms are
also involved in the immune rejection is still inconclusive.
We and other investigators previously reported the poten-
tial of histone methylation in regulating the expression of
genes associated with survival, proliferation and differenti-
ation of alloreactive T cells [6, 8], implying the novel epi-
genetic approaches capable of targeting a specific set of
genes in alloreactive T cells may also be useful for control-
ling T-cell-mediated allograft rejection.
Enhancer of Zeste homology 2 (EZH2), which methyl-
ates histone H3 on lysine 27 (H3K27me3), is an essential
epigenetic regulator of cell determination and function
through histone methylation. Evidence suggests that
overexpression of EZH2 is strongly associated with can-
cer progression and poor outcome in disparate cancers,
including hematologic and epithelial malignancies [9].
EZH2 not only facilitate the proliferation, survival and
transformation of cancer cells [10, 11], but also impact
the tumor immunity [12, 13]. Studies from pharmaceut-
ical company including GlaxoSmithKline and Novartis
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showed that, EZH2 has already been evaluated as thera-
peutic cancer target in drug discovery proceeding [14, 15].
Besides cancer cells, stem cells are also under the regula-
tion of EZH2. Disruption of EZH2 results in the shift of
mesenchymal stem cell lineage commitment [16], and
EZH2 is also associated with the engrafting potential of
hematopoietic stem and progenitor cells [17]. Several
articles published in 2015 reported the role of EZH2
in T lymphocytes, and found that constraint or deletion of
EZH2 dampened T cell differentiation and immune func-
tions both in vitro and in vivo [12, 18]. Ezh2-deficient T
effector cells neither provided a protective response to T.
gondii infection nor mediated autoimmune colitis, and
Ezh2-ablation in Treg failed to constrain autoimmune
colitis or experimental autoimmune encephalomyelitis
[18, 19]. Knockdown of human EZH2 in T cells elicited
poor anti-tumor immunity, whereas EZH2+CD8+ T cells
were associated with improved survival in patients [12].
3-deazaneplanocin A (DZNep) is an inhibitor of EZH2.
DZNep is recently considered as a potential epigenetic
drug, and exerts potent anti-proliferative and pro-
apoptotic effects on broad-spectrum carcinomas via dis-
ruption of the EZH2 pathway [20]. We first reported
DZNep arrested alloreactive T cell-mediated graft-versus-
host disease after hematopoetic stem cell transplantation
[6, 21]. This effect is associated with the ability of DZNep
to selectively deplete EZH2 specific to trimethylation of
histone H3K27me3, and activate proapoptotic gene Bim
repressed by EZH2 in antigenic-activated T cells [6], and
then hamper the pro-inflammatory function of allor-
eactive T cells without influencing the hematopoietic
chimerism and hematopoietic reconstitution [21], re-
vealing the possibilities of controlling immune rejec-
tion through the modulation of EZH2, while keeping
the functions of allografts.
As we previously reported, renal transplantation is a
classic model of solid organ transplantation, and acute
renal allograft rejection is actually a kind of inflamma-
tory response with significant accumulation and activa-
tion of monocytes, especially T lymphocytes in the graft
[22]. Therefore in this study, the renal transplantation
model were elected to investigate the effect of EZH2 and
DZNep in allogeneic T-cell-mediated acute rejection
(AR) in solid organ transplantation. We observed ele-
vated EZH2 in T cells after allogeneic renal transplant-
ation, and disruption of EZH2 by DZNep attenuated
acute renal allograft rejection, with ameliorated tissue in-
jury and inflammatory infiltration in the renal allograft.
The cellular mechanisms are related to the prohibited
activation and proliferation of alloreactive T cells, the
subsequent impaired inflammatory cytokine production,
and also the elevated apoptosis of alloreactive T cells in
both renal allografts and periphery. However, no pro-
moted Tregs was observed with the inhibition of AR by
EZH2 disruption. It is the first time we proved the rela-
tionship of EZH2 and the immune rejection after allo-
geneic renal transplantation, and suggested the potential
of pharmacologic inhibition of EZH2 by DZNep as a




Lewis rats were purchased from Beijing Vital River
Laboratory Animal Technology Company (Beijing, China).
Wistar rats were purchased from SLAC Laboratory
Animal Co., Ltd (Shanghai, China). Animals were housed
in specific pathogen-free facility at the Zhongshan
Hospital, Fudan University. All experimental protocols
were approved by Committee of Zhongshan Hospital,
Fudan University on Use and Care of Animals.
Flow cytometric analysis
Mononuclear cells (MNCs) of peripheral blood were
obtained by Ficoll density gradient centrifugation and
analyzed by flow cytometry. Monoclonal antibodies
with the following specificities were obtained from
BD Biosciences or eBioscience, or BioLegend (San
Diego, CA, USA): CD4 (OX-38), CD8 (OX-8), CD25
(OX-39), and Foxp3 (FJK-16 s). Foxp3/Transcription
Factor Staining Buffer Set was used for intracellular
staining Multiple-color flow cytometry analysis was
performed using FACS Aria (BD Biosciences).
Rat model of renal transplantation
Rats at 8–10 weeks, 180–220 g body weight were used
for transplantation. The transplantation was processed
as described previously [22]. Briefly, the donor kidney
removed from a Wistar or Lewis rat was transplanted
orthotopically into a unilaterally nephrectomized Lewis
recipient with end-to-end anastomosis of renal artery,
vein and ureter. Warm ischemia time did not exceed
40 min. No immunosuppressant were used in recipients.
The construction of rat renal transplantation model was
considered a success if the transplanted animal survived
for at least 4 days. DZNep was bought from the Cayman
Chemical Company (Ann Arbor, MI, USA). Recipient
rats were divided into three groups (n = 5 for each
group): (1) Isogenic group, rats transplanted with iso-
grafts (Lewis to Lewis); (2) Allogeneic group, rats
transplanted with allografts (Wistar to Lewis) and
with phosphate buffer (PBS) treatment; (3) DZNep
group, rats transplanted with allografts (Wistar to
Lewis) and with DZNep treatment (1 mg/kg/d DZNep
once per day after transplantation from day 0 to day
4, subcutaneous injection).
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Histologic analysis of renal allograft rejection
Paraffin sections of formalin-fixed renal grafts were
stained with hematoxylin and eosin (H&E), and were
reviewed for inflammatory infiltrating and tubule in-
jury. Tissues were graded using the Banff 97 grading
system by two pathologists who were blinded to the
diagnosis. The following Banff components were evalu-
ated: glomerulitis (g), tubulitis (t), interstitial inflammation
(i), arteriola hyalinosis (ah), and intimal arteritis (v). Glo-
merulitis (g) was scored as g0-g3: 0 %, <25 %, 25–75 %,
and >75 % of glomeruli, respectively; Tubulitis (t) was
scored as t0-t3: 0, foci with 1–4, foci with 5–10, foci
with >10 cells/tubular cross section, respectively; Inter-
stitial inflammation (i) was scored as i0-i3: <10 %, 10–
25 %, 26–50 %, >50 % of parenchyma inflamed, respect-
ively; Arteriola hyalinosis (ah) was scored as ah0-ah3:
no, mild-to-moderate, moderate-to-severe, severe PAS-
positive hyaline thickening, respectively; Intimal arteritis
(v) was scored as v0-v3: no, mild-to-moderate, severe
intimal arteritis, arterial fibrinoid change and/or trans-
mural arteritis with medial smooth muscle necrosis
with lymphocytic inflammation, respectively.
Immunohistochemistry (IHC)
Immunohistochemical staining of CD4, CD8, and CD68
(Abcam, Cambridge, UK) was performed on paraffin-
embedded or frozen sections using a DAKO ChemMate
EnVision Detection Kit (DAKO, Carpinteria, CA, USA)
as described previously [22]. Semi-quantification for
IHC staining slides were performed under high power
filed (HPF, 400×).
Detection of apoptosis
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling (TUNEL) staining kit (Millipore,
MA, USA) was used to detect apoptotic cells in renal
grafts, and the manufacturer’s instructions were followed.
Semi-quantification for apoptotic cells were performed
under high power filed (HPF, 400×).
Western blot
CD3+CD25+ T cells were sorted out from MNCs by flow
cytometry. The purity of sorted cells in this study was
consistently more than 99 %. Then, cells were directly
lysed with RIPA containing protease and phosphatase in-
hibitors (Roche Applied Science, Indianapolis, IN, USA)
and proteins were separated by 10 % SDS-PAGE after
denaturation. Immunoblot analysis was performed by
initial transfer of proteins onto polyvinylidenefluoride
membranes using Mini Trans-Blot (Bio-Rad Laboratories,
Richmond, VA, USA) and followed by a blocking step with
5 % nonfat dried milk plus 0.1 % Tween 20 for 2 h at
room temperature and exposed to primary antibodies di-
luted 1000-fold that recognized EZH2 and actin overnight
at 4 °C and subsequently washed. The blots were then in-
cubated with a secondary antibody conjugated with Horse
Radish Peroxidase diluted 5000-fold for 1 h at room
temperature. Signals were detected by FluorChem E sys-
tem (Alpha Innotech Corp, Santa Clara, CA, USA).
Cytokine analysis
The levels of IFN-γ, TNF-α, IL-2, IL-17, IL-4 and IL-10 in
plasma were assessed with enzyme-linked immunosorbent
assay (ELISA) kits according to the manufacturer’s in-
structions (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Data presented as means ± SEM, and Kruskal-Wallis
test was used for statistics among the three groups.
Differences were considered statistically significant if
the p value was less than 0.05.
Results
Inhibition of EZH2 by DZNep ameliorated acute renal
allograft rejection
Rat renal transplantation was performed and the recipi-
ents were sacrificed on day 5 after transplantation. Since
in this study, recipient rats were processed by unilat-
erally nephrectomy and orthotopical transplantation, the
survival status and urine data would not represent the
functions of allografts. Histological examination showed
that the acute graft rejection occurred in allogeneic
group, as evidenced by acute tubular injury, diffuse
heavy inflammatory infiltration with severe glomerulopa-
thy, intimal arteritis and arteriola hyalinosis. However,
when treated with DZNep, the allograft tissue damage
and inflammatory infiltration were remarkably attenu-
ated (Fig. 1a and b). The TUNEL staining also showed
that, allografts without DZNep treatment had more
apoptotic cells, which mainly located on tubular and
interstitial areas, and the DZNep treatment also reduced
the apoptotic cells in allografts (Fig. 1a and c), suggest-
ing that administration of DZNep can protect allografts
with reduced tissue inflammation and damages. Further,
in order to confirm the role of EZH2 inhibition by
DZNep in renal transplantation, the protein levels of
EZH2 were determined by western blot. As we expected,
the declined EZH2 in the alloreactive T cells were ob-
served in DZNep-treated recipients (Fig. 1d and e). All
those data demonstrated that in rat renal transplant-
ation, disruption of EZH2 by DZNep ameliorated acute
renal allograft rejection.
DZNep treatment prohibited T cell infiltrating in allograft
We next investigated the mechanisms by which DZNep
protects the renal grafts. Since alloreactive T cells are the
direct mediator of acute rejection, their infiltrating status
in renal grafts was then detected by IHC. We found that,
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renal grafts in allogeneic transplantation had elevated
CD4 and CD8 staining as compared with those in isoge-
neic transplantation, while DZNep treatment in allogeneic
transplantation prohibited the elevation (Fig. 2a). Semi-
quantification analysis further confirmed the significance
of T cell infiltrating differences when DZNep was applied
(Fig. 2b). However, although the infiltration of CD68+
macrophages in allograft was increased, it seems that
DZNep treatment did not significantly suppress the
macrophage infiltration (Fig. 2a and b). These data
suggested that DZNep can inhibit the accumulation
of alloreactive T cells in allografts, and also implying
the possibility of impacted T cell response in DZNep
administration.
DZNep blemished the activation and survival of
alloreactive T cells
The alloreactive T cell response includes the activation
in response to allo-antigens and the survival after activa-
tion. Therefore, the activation and apoptosis status of re-
cipient T cells were then tested by flow cytometry. On
day 5 after transplantation, recipients with DZNep treat-
ment showed lower frequency of CD25 expression on
both CD4+ and CD8+ T cells, as compared with those in
allogeneic group (Fig. 3a and b), and also had reduced
absolute numbers of activated T cells in periphery
(Fig. 3c), indicating that DZNep are able to inhibit T cell
activation in recipients. On the other hand, increased
AnnexinV+ proportions in both CD4+ and CD8+ T cells
Fig. 1 Attenuated acute renal allograft rejection by EZH2 inhibition. Rat renal transplantation was performed as described in methods. Groups are
classified in Methods. Renal grafts and recipient periphery blood were collected on day 5 after transplantation for analysis. (a) H&E and TUNEL
staining were performed for renal grafts. (b) Histochemical quantitative data of Banff components including glomerulitis (g), tubulitis (t), interstitial
inflammation (i), arteriola hyalinosis (ah), and intimal arteritis (v) was evaluated. (c) Semi-quantification apoptotic cells in renal graft parenchyma
were examined. (d, e) EZH2 protein levels in peripheral CD3+CD25+ T cells were examined by western blot (d), and quantification was done by
densitometry of western blot bands (normalized to actin) (e). *, p < 0.05, Kruskal-Wallis test
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were observed in DZNep-treated recipients, as com-
pared with those in allogeneic group (Fig. 3d and e), sug-
gesting a pro-apoptotic role of DZNep in alloreactive T
cells. These data suggest that, EZH2 are promotive for
alloreactive T cell response and DZNep can blemish the
activation and survival of alloreactive T cells after renal
transplantation.
DZNep ameliorated local and systemic inflammatory
environment
Alloreactive effector T cells mediate allograft injury
through direct contact with tubular epithelial cells (cell-
mediated cytotoxicity) and locally released cytokines.
We have demonstrated that DZNep ameliorated local in-
flammation in renal grafts with less CD4+ T and CD8+ T
cells infiltration in the interstitial area of renal allografts
(Fig. 2a and b). We also tested the inflammatory
cytokine expression in peripheral blood by ELISA. Typ-
ical pro-inflammatory cytokines, such as TNF-α, IFN-γ,
IL-17, and IL-2, which can drive cellular response, im-
pair the allograft function and intensify T-cell mediated
rejection after allogeneic organ transplantation [23, 24],
were found to be significantly reduced in DZNep-treated
recipients, in contrast to those in allogeneic group after
renal transplantation (Fig. 4a). Surprisely, we also found
that the levels of IL-4 and IL-10 were also declined by
DZNep administration (Fig. 4b), which implied that in-
hibition of EZH2 by DZNep did not function through
elevating Th2 response to suppress Th1 response. The
controversial roles of IL-4 and IL-10 in renal rejection
are discussed in the section of Discussion. Taken to-
gether, these data suggest that DZNep can control the
local and systemic inflammatory environment, which is
promotive for renal graft survival and function.
Fig. 2 Diminished alloreactive T cell infiltration with DZNep treatment. IHC staining of CD4, CD8 and CD68 on renal grafts (a), and the
semi-quantification of CD4+ and CD8+ lymphocytes and CD68+ macrophages (b). *, p < 0.05, Kruskal-Wallis test
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Fig. 3 DZNep inhibits the survival of alloreactive T cells. Peripheral blood was harvested from recipient rats on day 5 after transplantation for flow
cytometry analysis. Percentages of peripheral CD4+CD25+ and CD8+CD25+ cells were determined (a and b). The absolute numbers of peripheral
CD4+CD25+ and CD8+CD25+ cells were also calculated (c). Percentages of Annexin V+ CD4+ and Annexin V+ CD8+ were presented (d and e). *,
p < 0.05, Kruskal-Wallis test
Fig. 4 DZNep inhibits inflammatory cytokines in periphery. a, b ELISA assays were performed to test the plasma cytokine levels on day 5 after
transplantation. IFN-γ, TNF-α, IL-17, and IL-2 levels were presented (a), IL-4 and IL-10 levels were shown (b). *, p < 0.05, Kruskal-Wallis test
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DZNep protected renal allografts through a Treg-irrelevant
pathway
Regulatory T cells (Tregs) that express the transcription
factor Foxp3 are a highly suppressive population, and
are considered to be critical for the maintenance of tol-
erance to self-components [25]. Some reports suggested
that the induction of immunologic tolerance of organ
transplantation was characterized by reduction of allor-
eactive effector T cells and increased numbers of Tregs
[26, 27]. However, in this study, we did not observe
increased Tregs with DZNep treatment after transplant-
ation. In contrast, peripheral CD4+Foxp3+ Tregs in
DZNep-treated recipients was declined when compared
to recipients with AR (Fig. 5a and b), and in renal grafts,
diminished Foxp3+ T cell infiltration was also observed
when DZNep was applied to recipients (Fig. 5c and d).
These findings imply that the suppression of acute renal
rejection by DZNep is not mediated through the im-
munosuppression functions of Treg, in contrast, inhib-
ition of EZH2 by DZNep blemished recipient T cell
response which may also include the Treg differentiation
after transplantation.
Discussion
Lifelong immunosuppression is associated with severe
side effects, such as diabetes, cardiovascular diseases,
cancer, infection, and allograft toxicity, thereby limiting
long-term allograft survival [28]. Therefore, better un-
derstanding of the allogeneic immune response and
identification of new therapeutic targets are still needed.
Here we identify that histone methyltransferase EZH2 is
critical for alloreactive T cell response after allogeneic
renal transplantation, and inhibition of EZH2 by DZNep
can protect the allograft from inflammatory infiltration
and promote graft survival.
Although EZH2 and its epigenetic modification func-
tion have already been considered to be important for
T-cell responses, it’s still the first time to directly dem-
onstrate that EZH2 is involved in the pathogenesis of
solid organ transplantation and promotes acute allo-
geneic rejection. In rat transplantation model, disrup-
tion of EZH2 by DZNep suppressed alloreactive T cell
activation, limited their survival, and controlled the
local and systemic inflammatory environments.
The role of inflammatory cytokines and particularly
the role of Th2 cytokines IL-4 and IL-10 in the course
of allograft acute rejection are subjected of intensive re-
search for decades, but now are still controversial. In-
creased levels of IL-4 and IL-10 were observed in the
immune rejection courses of several organs and tissues,
including skin and kidney [29, 30]. In animals, IL-4 me-
diated tissue allograft eosinophil infiltration is associated
with interstitial fibrosis [29], and induction of a Th2 allo-
geneic response resulted in de novo development of
chronic rejection [31]. In patients, higher levels of IL-4
prior to and shortly after transplantation may have pro-
tective effects on graft survival. However, a prolonged,
increased production of IL-4 after transplantation also
contribute to acute allograft rejection episodes [32]. Al-
though IL-10 has been shown to have the suppressive
function on antigen-specific effector cell responses [33],
it was also reported as a stimulator of the immune
Fig. 5 DZNep does not increase the differentiation of Tregs. The percentages of peripheral CD4+Foxp3+ were examined by flow cytometry
(a and b). IHC staining of Foxp3 were performed on renal grafts (c), IHC semi-quantification of Foxp3+ cells were analyzed (d). *, p < 0.05,
Kruskal-Wallis test
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system, inducing the differentiation and proliferation of
B cells, thus leading the immune response toward the
humoral pathway and enhancing antibody responses
against the graft [34]. Here DZNep treatment can signifi-
cantly reduce the levels of both IL-4 and IL-10, so we
can conjecture that DZNep may be able to further sup-
press the induction of chronic renal rejection, delay the
course of interstitial fibrosis and benefit long-term allo-
graft survival.
It is interesting that DZNep treatment resulted in less
CD4+Foxp3+ Tregs in peripheral blood and renal allo-
grafts. This coincides with our previous observations
that DZNep treatment decreased both frequency and
number of peripheral Tregs during GVHD [6]. This
phenomenon can be explained by two aspects. First, in
the present study, DZNep treatment not only prohibits
the infiltration of T cell in allograft, but also suppresses
the activation and survival of alloreactive T cells in the
periphery, implying that DZNep induces apoptosis of ac-
tivated T cells in the lymph node and no activated lym-
phocytes in the periphery are able to home in the
allograft. Therefore, the lack of inflammatory cells in
blood and allograft might explain the lack of Tregs at
that site and low levels of both Th1 and Th2 cytokines
in the plasma. These results are consistent with the
study showing that deficiency of EZH2 dampened Th
differentiation and in Treg was associated with a defect
in Treg stability, and EZH2 may promote the mainten-
ance of Foxp3 expression during Treg cell responses
[18, 19]. Another, although evidence accumulated in
past decade supports the critical role of Tregs in the
suppression of alloimmune responses, there’s still con-
flicting results emerged from many studies and may
have generated more confusion than clarification. Several
studies showed poor correlation between Tregs infiltration
and allogeneic graft status, based on Foxp3 analysis from
graft biopsy cores, some studies confirmed higher Foxp3
expression in the grafts exhibiting cellular acute rejection
[35, 36]. It is also reported that Tregs are first activated in
the allograft, and subsequently migrate to the draining
lymph nodes and peripheral blood, where they suppress
the alloantigen-specific immune response [37]. These
findings are helping explain higher Foxp3-expressing
Treg-levels in peripheral blood and allografts in recipient
rats with acute rejection. Taken together, these observa-
tions suggest that the protective effect of DZNep on renal
allografts was realized through a pathway irrelevant of in-
creased Tregs in peripheral blood and renal allografts.
In this study, we transplanted renal grafts orthotopi-
cally into unilaterally nephrectomized recipient rats,
that’s why we did not show the survival curves of graft/
recipient rats. Although renal allograft function in terms
of serum creatinine and urine nitrogen levels are also in-
valid for evaluation, the pathophysiological process of
AR and histological change of renal grafts are not influ-
enced. There are many merits to use unilaterally nephrec-
tomized recipients model. First, this model is also well
qualified for investigating the allogeneic immune re-
sponse, including the pathology of allografts and allogen-
eic T cells responses. Second, unilaterally nephrectomized
recipient possess a better post-transplant condition com-
pared to bilaterally nephrectomized recipients, especially
recipients with delayed graft function, so as to enhance
the steadiness of renal transplant model.
Based on our and other research results, DZNep is dif-
ferent from traditional immunosuppressive agents such
as cyclosporine A and tacrolimus. The first reason is the
reversibility of DZNep’s effect [38]. Secondly, DZNep
possesses broad potent antiviral activity, including
against rotavirus, vesicular stomatitis virus and vaccinia
virus [39, 40]. In particular, this antiviral spectrum of
DZNep extends to human cytomegalovirus, which is
capable of causing serious infection in transplanted re-
cipients with reduced immune functions [40]. Thirdly,
although pharmacological EZH2 inhibition by DZNep
shows broad anti-tumor effect in several cancers, includ-
ing but not limited to prostate cancer, breast cancer,
acute myeloid leukemia, and particular renal cell carcin-
oma [41–44]. All those data imply that DZNep may not
be limited to an immunosuppressive agent for treating
allografts rejection, but also a potential drug for prevent-
ing/treating virus infections and malignant tumors after
organ transplantation. However, the side effects should
be brought to consideration as well. As we introduced
previously, EZH2-abalation affects the regulatory T cell
generation, increased the risk of infection, and also
dampen the immune response against cancerous cells
[12, 18, 19]. Therefore, more investigations should be
processed to carefully evaluate the effects of DZNep be-
fore clinical application.
Conclusions
To summarize, we have demonstrated that inhibition of
histone methyltransferase EZH2 by DZNep can protect
renal allograft from acute rejection. It is the first time we
demonstrated the therapeutic function of DZNep in solid
organ transplantation, and there are still more investiga-
tions required for comprehensive understanding of mech-
anisms. For instance, the impact of DZNep on other
immune cells, and how to optimize the DZNep treatment,
are all needed to develop DZNep for clinical use.
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